GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Templates Inc (NAS:MTEM) » Definitions » Beneish M-Score
中文

Molecular Templates (Molecular Templates) Beneish M-Score : 3.41 (As of Apr. 25, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Molecular Templates Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 3.41 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Molecular Templates's Beneish M-Score or its related term are showing as below:

MTEM' s Beneish M-Score Range Over the Past 10 Years
Min: -4.34   Med: -3.01   Max: 6.04
Current: 3.41

During the past 13 years, the highest Beneish M-Score of Molecular Templates was 6.04. The lowest was -4.34. And the median was -3.01.


Molecular Templates Beneish M-Score Historical Data

The historical data trend for Molecular Templates's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Templates Beneish M-Score Chart

Molecular Templates Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.99 -4.34 -3.08 -3.84 3.41

Molecular Templates Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.84 -1.15 1.78 1.19 3.41

Competitive Comparison of Molecular Templates's Beneish M-Score

For the Biotechnology subindustry, Molecular Templates's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Templates's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Templates's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Molecular Templates's Beneish M-Score falls into.



Molecular Templates Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Molecular Templates for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 1.6268+0.892 * 2.664+0.115 * 0.7776
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2707+4.679 * 0.845576-0.327 * 0.7073
=3.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.25 Mil.
Revenue was 6.639 + 5.732 + 6.627 + 33.627 = $52.63 Mil.
Gross Profit was 6.639 + 5.732 + 6.627 + 33.627 = $52.63 Mil.
Total Current Assets was $16.77 Mil.
Total Assets was $35.38 Mil.
Property, Plant and Equipment(Net PPE) was $16.55 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.65 Mil.
Selling, General, & Admin. Expense(SGA) was $18.90 Mil.
Total Current Liabilities was $17.32 Mil.
Long-Term Debt & Capital Lease Obligation was $9.74 Mil.
Net Income was -3.948 + -4.153 + -10.868 + 10.845 = $-8.12 Mil.
Non Operating Income was 1.273 + 0.805 + 1.699 + 0 = $3.78 Mil.
Cash Flow from Operations was -5.287 + -7.534 + -9.638 + -19.361 = $-41.82 Mil.
Total Receivables was $0.00 Mil.
Revenue was 2.611 + 4.24 + 4.417 + 8.486 = $19.75 Mil.
Gross Profit was 2.611 + 4.24 + 4.417 + 8.486 = $19.75 Mil.
Total Current Assets was $68.30 Mil.
Total Assets was $97.55 Mil.
Property, Plant and Equipment(Net PPE) was $25.76 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.38 Mil.
Selling, General, & Admin. Expense(SGA) was $26.20 Mil.
Total Current Liabilities was $57.08 Mil.
Long-Term Debt & Capital Lease Obligation was $48.40 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.25 / 52.625) / (0 / 19.754)
=0.004751 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(19.754 / 19.754) / (52.625 / 52.625)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (16.772 + 16.554) / 35.383) / (1 - (68.298 + 25.764) / 97.548)
=0.058135 / 0.035736
=1.6268

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=52.625 / 19.754
=2.664

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(7.383 / (7.383 + 25.764)) / (6.645 / (6.645 + 16.554))
=0.222735 / 0.286435
=0.7776

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(18.897 / 52.625) / (26.2 / 19.754)
=0.359088 / 1.326314
=0.2707

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((9.742 + 17.321) / 35.383) / ((48.399 + 57.082) / 97.548)
=0.764859 / 1.081324
=0.7073

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-8.124 - 3.777 - -41.82) / 35.383
=0.845576

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Molecular Templates has a M-score of 3.41 signals that the company is likely to be a manipulator.


Molecular Templates Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Molecular Templates's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Templates (Molecular Templates) Business Description

Traded in Other Exchanges
N/A
Address
9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer.
Executives
Maurizio Voi officer: Chief Medical Officer 4 MAGUIRE ROAD, LEXINGTON MA 02421
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Sean Mclennan officer: CFO & Treasurer C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729
Kevin M. Lalande director, 10 percent owner 201 WEST 5TH STREET, AUSTIN TX 78701
Shv Management Services, Llc 10 percent owner FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701
Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Jason S. Kim officer: See Remarks 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Patrick G Enright 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Bakker Juliet Tammenoms 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
David Hirsch director, 10 percent owner C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Longitude Venture Partners Iii, L.p. 10 percent owner 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Scott D Morenstein director C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019